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Irinotecan (CPT-11) has been shown to exhibit excellent antitumour activity against small-cell lung cancer (SCLC). A multi-
institutional phase II study was therefore conducted to evaluate the efficacy and toxicity of CPT-11 combined with cisplatin (CDDP)
and etoposide (ETOP) (PEI regimen) for the treatment of sensitive relapsed SCLC. Patients who responded to first-line
chemotherapy but relapsed more than 8 weeks after the completion of first-line therapy (n¼40) were treated using the PEI regimen,
which consisted of CDDP (25mgm
 2) weekly for 9 weeks, ETOP (60mgm
 2) for 3 days on weeks 1, 3, 5, 7, and 9, and CPT-11
(90mgm
 2) on weeks 2, 4, 6, and 8 with granulocyte colony-stimulating factor support. Five complete responses and 26 partial
responses were observed, and the overall response rate was 78% (95% confidence interval 61.5–89.2%). The median survival time
was 11.8 months, and the estimated 1-year survival rate was 49%. Grade 3/4 leucocytopenia, neutropenia, and thrombocytopenia
were observed in 55, 73, and 33% of the patients, respectively. Nonhaematological toxicities were mild and transient in all patients. In
conclusion, the PEI regimen is considered to be highly active and well tolerated for the treatment of sensitive relapsed SCLC.
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Small-cell lung cancer (SCLC) is one of the most chemosensitive
solid tumours, and first-line combination chemotherapy improves
survival. However, despite a high response rate to chemotherapy,
the majority of SCLC patients relapse. At the time of recurrence,
the tumour is broadly resistant to second-line chemotherapy and is
lethal within a few to several months (Glisson, 2003). The further
development of not only first-line chemotherapy but also of
effective salvage chemotherapies is needed.
In predicting the efficacy of salvage chemotherapy, two major
factors are important: the response to the initial chemotherapy and
the duration of time between the last exposure to chemotherapy
and the confirmation of recurrence (Postmus et al, 1987; Giaccone
et al, 1988; Ardizzoni et al, 1997; Ebi et al, 1997). Based on these
factors, relapsed SCLC is now commonly classified into two main
groups. Patients who both respond to the initial chemotherapy and
relapse more than 2 or 3 months after the completion of
chemotherapy are considered to be ‘sensitive relapse’ patients,
while patients whose tumour is stable or progresses during the
initial chemotherapy or who have a recurrence within 2 or 3
months after the completion of chemotherapy are considered to be
‘refractory relapse’ patients (Giaccone et al, 1988). Since the
outcomes of salvage chemotherapy for relapsed SCLC patients are
different between these two groups, the ratios of sensitive and
refractory cases must be carefully considered when evaluating the
results of clinical trials for second-line chemotherapy.
The combination of cisplatin (CDDP) and etoposide (ETOP) (PE
regimen) has been the standard chemotherapeutic regimen for SCLC
(Fukuoka et al, 1991; Ihde, 1992; Roth et al, 1992; Aisner, 1996).
Moreover, PE is a reasonable second-line chemotherapy for relapsed
SCLC after combination chemotherapy consisting of cyclopho-
sphamide, doxorubicin (ADM), and vincristine (VCR) (CAV regi-
men); the likelihood of a response to this regimen is 40–50% (Evans
et al, 1984; Porter et al, 1985). Since PE has a relatively mild toxicity
profile, other cytotoxic agent can be combined with PE.
Irinotecan (CPT-11), a camptothecin derivative topoisomerase I
inhibitor, has been shown to exhibit excellent antitumour activity
against SCLC in monotherapy and in combination with CDDP
(Masuda et al, 1992; Kudoh et al, 1998). Based on these results, the
Japan Clinical Oncology Group (JCOG) conducted a randomised
phase III trial comparing CPT-11 and CDDP (IP regimen) with
standard PE for previously untreated extensive stage (ED) SCLC
(JCOG 9511) (Noda et al, 2002). The response rates were
significantly higher for IP than for PE, and overall survival was
also significantly better for IP than for PE. This was the first study
to show the superiority of any one regimen over PE for the
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ltreatment of ED SCLC, and IP has become one of the standard
regimens for ED SCLC in Japan. Thereafter, several clinical trials of
CPT-11-containing regimens for patients with limited disease
(LD), ED, and relapsed SCLC have been conducted by Japanese
clinical study groups (Masuda et al, 1998; Mori et al, 2002; Sekine
et al, 2002).
Consequently, a phase I trial of CPT-11 combined with weekly
CDDP (25mgm
 2) and biweekly ETOP (60mgm
 2) (PEI regimen)
was conducted, and the recommended dose of 90mgm
 2 of CPT-
11 was repeated every 2 weeks (JCOG 9507) (Sekine et al, 2003).
This regimen showed promising antitumour activity in patients
with untreated ED SCLC (response rate, 91%, 1-year survival rate
46%). Moreover, since the drug dose and treatment schedule can
be easily modified in a weekly regimen, this protocol is considered
to be suitable for relapsed SCLC patients, who usually present with
severe haematological toxicities during salvage chemotherapy
because of poor bone marrow reserve (Masuda et al, 1990; Faylona
et al, 1995).
Based on these results, we conducted two phase II trials to
evaluate the efficacy and toxicities of PEI in patients with sensitive
and refractory relapsed SCLC, separately. In this paper, the final
results for the sensitive relapsed SCLC group are reported.
PATIENTS AND METHODS
Patient selection
Patients with histologically or cytologically confirmed SCLC who
respond to first-line chemotherapy or chemoradiotherapy and
relapsed more than 8 weeks after the completion of first-line
treatment were candidates for the present study. Additional
eligibility criteria were as follows: (1) age of 75 years or younger;
(2) performance status of 0–2 on the Eastern Cooperative
Oncology Group scale; (3) measurable disease; (4) adequate organ
function as documented by a 4.0 10
9l
 1pWBC
countp12.0 10
9l
 1, haemoglobin level of X9.0gdl
 1, platelet
count of X100 10
9l
 1, total serum bilirubin level of
p1.5mgdl
 1, a hepatic transaminase level of p2 times the
institutional upper limit of normal, a serum creatinine level of
p1.5mgdl
 1; and (5) written informed consent. Patients were not
eligible for the study if they had experienced any of the following
events: (1) massive pleural effusion requiring drainage; (2) prior
radiotherapy with an irradiated area larger than one-third of the
bone marrow volume; (3) active infection; (4) contraindications
for the use of CPT-11, including diarrhoea, ileus, interstitial
pulmonary fibrosis, massive ascites, or hypersensitive reaction to
CPT-11; (5) serious concomitant medical illness, including severe
heart disease, uncontrollable diabetes mellitus or hypertension; or
(7) pregnancy or lactation. This study was approved by the
institutional review board at each participating institution.
Treatment schedule
Figure 1 shows the treatment schema of the PEI regimen. CDDP
(25mgm
 2) was administered intravenously (i.v.) over 60min on
day 1 and at 1-week intervals for 9 weeks; ETOP (60mgm
 2) was
administered i.v. over 60min on days 1–3 of weeks 1, 3, 5, 7, and 9;
and CPT-11 (90mgm
 2) was administered i.v. over 90min on day
1 on weeks 2, 4, 6, and 8. Hydration (2000ml) and granisetron
(40mgkg
 1) were given on day 1. After day 1 on week 2,
granulocyte colony-stimulating factor (G-CSF) (50mgm
 2) was
administered routinely according to JCOG 9507 on days when the
cytotoxic drugs were not given, unless the WBC count exceeded
10.0 10
9l
 1. Patients were expected to complete at least six cycles
of this regimen; if the toxicities were acceptable and the tumour
responded to the treatment, a maximum of nine cycles of
chemotherapy were performed.
Toxicity assessment and treatment
During the course of treatment, complete blood cell counts
and differential counts were analysed twice a week, and routine
chemistry measurements and a chest X-ray were performed once a
week. Toxicity was graded according to the toxicity criteria of the
JCOG (Tobinai et al, 1993), a modified version of the
NCI Common Toxicity Criteria issued in 1991. Grade 4 neutrope-
nia was defined as o0.5 10
9l
 1, and grade 3 neutropenia
was defined as between (and including) 0.5–1.0 10
9l
 1, accord-
ing to the JCOG criteria. The second and subsequent cycles of
chemotherapy were delayed for 1 week if one of the following
toxicities was noted on day 1: a WBC count of o2.0 10
9l
 1,a
platelet count of o50 10
9l
 1, a serum creatinine level of
X2.0mgdl
 1, an elevated hepatic transaminase level or total
serum bilirubin of grade 2 or higher, diarrhoea of grades 1–2,
fever X381C, or a performance status of 3. The treatment was
terminated if the above-mentioned criteria did not disappear in 3
weeks or if one of the following severe nonhaematological
toxicities was noted: diarrhoea of grade 2 lasting for more than 1
week, diarrhoea of grade 3, neurotoxicity of grade 3, or drug-
induced pneumonitis.
Dose modifications for toxicity
The CPT-11 dosage was reduced to 67.5mgm
 2 (25% reduction)
in subsequent cycles if one of the following toxicities was noted: a
WBC count of o1.0 10
9l
 1, or a platelet count of o25 10
9l
 1.
If the above-mentioned toxicities reappeared after a 25% reduction
in the dosage, the CPT-11 dosage was further reduced to
50mgm
 2 (44% reduction). Since CDDP (25mgm
 2) and ETOP
(60mgm
 2) in this regimen were relatively low dose, no dose
modifications for these drugs were permitted.
Pretreatment evaluation
Pretreatment assessment included a complete blood cell count,
differential counts, routine chemistry measurements, creatinine
clearance, blood gas analysis, electrocardiogram, chest X-rays,
computed tomography (CT) scan of the chest, brain CT scan or
magnetic resonance imaging (MRI), abdominal CT scan or
ultrasound sonography, radionuclide bone scan, and bone X-rays,
if indicated.
Response evaluation
Objective tumour responses were evaluated in all enrolled patients
according to the WHO criteria issued in 1979 (WHO, 1979). A
complete response (CR) was defined as the disappearance of all
known disease for at least 4 weeks with no new lesions appearing.
A partial response (PR) referred to a decrease in the total tumour
size of at least 50% for at least 4 weeks without the appearance of
new lesions. No change (NC) was defined as the absence of a
partial or complete response and the appearance of no progressive
or new lesions for at least 4 weeks. Progressive disease (PD) was
Figure 1 Treatment schedule.
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ldefined as a 25% or greater increase in the size of any measurable
lesion or the appearance of new lesions. Patients whose responses
were not evaluated were included in the analysis as not evaluable
(NE).
Statistical methods
The primary end point of this study was the response rate, defined
as the proportion of patients whose best response was CR or PR
among all eligible patients, and its confidence interval was based
on an exact binomial distribution. Simon’s two-stage minimax
design was used to determine the sample size and decision criteria.
Assuming that a response rate of 40% in eligible patients would
indicate a potential usefulness of the regimen while a rate of 20%
would be the lower limit of interest and that alpha¼0.05 and
beta¼0.20, the estimated number of required patients was 33
(Simon, 1989). Finally, this regimen would be considered worthy of
further testing if 11 (33%) or more eligible patients showed an
objective response. At the first stage decision, this regimen would
be rejected if four (22%) or fewer of 18 eligible patients had an
objective response. Thus, we determined that the sample size
would be 35 registered patients. The planned accrual period was 2
years, and the follow-up period was set as 1 year after the
completion of accrual. Secondary end points were toxicity and
overall survival. The duration of overall survival was measured
from the date of registration to the date of death from any cause or
the last follow-up examination. Progression-free survival was
calculated from the date of registration until evidence of PD. All
patients started the treatment within 1 week of registration. The
survival distribution was estimated by the method of Kaplan and
Meier (1958).
RESULTS
Patient characteristics
From October 1998 to March 2001, 40 patients were enrolled in
this study. The first-stage decision was made in October 1999,
when 22 patients were registered. Three CRs and 13 PRs
were observed in 18 analysed patients, resulting in a response
rate of 89% (95% confidence interval (CI), 65.3–98.6%). This
result did not meet the criteria for stopping the study as defined in
the protocol, and the study was continued. At the time of the final
analysis, there were three censored cases (8%). The median follow-
up period for these cases was 25.5 months (range, 4.4–46.1
months).
The clinical characteristics of the enrolled patients are listed in
Table 1. Of the 40 patients in the total, 29 (73%) were male
and 11 (27%) were female; the median age was 67 years. A total
of 39 patients (97%) had a good performance status of 0 or 1.
The extent of the disease at the time of recurrence was LD in five
patients (12%) and ED in 35 (88%). All 40 patients had
been previously treated using platinum-based chemotherapy,
such as PE in 11 patients, carboplatin plus ETOP in 11, PE plus
weekly CDDP/VCR/ADM/ETOP (CODE) in six, CDDP plus CPT-11
in six, PEI in two, and other regimens in four. Eight (20%) of these
patients received thoracic radiotherapy. All patients were eligible,
and the toxicity and efficacy of the regimen was evaluated in all 40
patients.
Compliance with treatment
A total of 251 treatment cycles were administered, with a median of
six cycles per patient (range, 1–9 cycles). A total of 32 patients
(80%) completed six or more cycles of chemotherapy, and the
median number of weeks for completing six cycles of chemother-
apy was 7 weeks (range 6–10 weeks). Eight patients could not
complete the planned six or more cycles for the following reasons:
toxicities in four cases (grades 4 and 3 diarrhoea, grade 3 liver
dysfunction, and grade 3 erythema); patient refusal in three cases;
and PD in one case. Six patients (15%) had their dosage of CPT-11
reduced because of leucocytopenia in three, thrombocytopenia in
two, and both in one.
Clinical response and survival
All the patients were included in the analyses of tumour response
and survival. Five CRs (13%) and 26 PRs (65%) were observed, for
an overall response rate of 78% (31 out of 40 patients; 95% CI,
61.5–89.2%). Four NC, four PD, and one NE were also observed.
One patient was lost to follow-up and only two patients were still
alive as of April 16, 2003. The median survival time (MST) was 11.8
months (95% CI, 10.1–13.5 months), and the estimated 1-year
survival rate was 49% (Figure 2).
Table 1 Patient characteristics
Total no. of patients 40
Age, median (range) 67 (41–74)
Sex
Male 29
Female 11
ECOG performance status
09
13 0
21
Disease extent at relapse
Limited disease 5
Extensive disease 35
Prior chemotherapy
CDDP/ETOP 11
CBDCA/ETOP 11
CDDP/ETOP/CODE 6
CDDP/CPT-11 6
PEI 2
Others 4
Prior thoracic radiotherapy 8
ECOG¼Eastern Cooperative Oncology Group; CDDP¼cisplatin; ETOP¼
etoposide; CBDCA¼carboplatin; CODE¼cisplatin/vincristine/doxorubicin/etopo-
side; CPT-11¼irinotecan; PEI¼cisplatin/etoposide/irinotecan.
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Figure 2 Overall survival (n¼40).
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lSite of first relapse and progression-free survival
The majority of patients (n¼30, 75%) experienced a systemic
relapse after completing PEI, including 17 patients (43%) with
central nerve metastases. Six patients (15%) developed only a
locoregional recurrence, and one had no recurrence and died of
acute myocardial infarction. No data on recurrence patterns were
available in three patients because these patients were followed up
at other hospitals. In all, 13 patients received additional
chemotherapy treatment after recurrence (no data on response
to third-line chemotherapy were available), while four patients
underwent palliative chest radiotherapy and 18 underwent whole-
brain irradiation for cerebral metastases. One patient, who
achieved a CR by this regimen, developed a locoregional
recurrence and underwent a right upper lobectomy. He has not
experienced any further relapse and is still alive. The median
progression-free survival period was 5.0 months (95% CI, 4.1–5.9
months) (Figure 3).
Toxicities
All the patients were included in the toxicity analysis. Severe
toxicities were mainly haematological. Grades 3–4 leucopenia,
neutropenia, and thrombocytopenia were observed in 22 (55%), 29
(73%), and 13 (33%) patients, respectively (Table 2). Nonhaema-
tological toxicities were mild and transient in all patients. Grades
3–4 diarrhoea was noted in only three patients (8%) (Table 3). No
treatment-related deaths occurred.
DISCUSSION
Despite a high response rate to first-line chemotherapy, most
patients with SCLC experience a relapse within a year of the
completion of therapy (Hansen, 1992). Although many relapsed
patients in good physical condition undergo second-line che-
motherapy, the results are disappointing. The obtained response is
usually brief, and the median survival period is generally less than
4 months (Albain et al, 1993; Glisson, 2003).
Although one phase III trial for patients with relapse SCLC
comparing the use of topotecan with CAV has been reported (von
Pawel et al, 1999), a standard treatment for relapsed SCLC has not
been agreed upon. However, the repeated use of the original
induction regimen is the most popular treatment for sensitive
relapsed patients. Reinduction chemotherapy has been reported to
produce a response rate of 50%, and patients who relapsed more
than 3 months after the end of their previous chemotherapy
regimen were sensitive to reinduction chemotherapy (Giaccone
et al, 1987; Postmus et al, 1987). Giaccone et al (1988) suggested
that sensitive tumour cells, which were not completely eradicated
by the induction chemotherapy, regrow spontaneously after the
suspension of chemotherapy, eventually constituting a clinically
significant part of the tumour burden. In the present study, two
patients received the PEI regimen as a reinduction chemotherapy,
and both patients showed PRs.
Many clinical trials of salvage chemotherapy for relapsed
SCLC have been reported. In these studies, the single administra-
tion of CPT-11 or ETOP produced good results, with response
rates of 16–47% and an MST of 3.5–6.2 months (Einhorn et al,
1990; Johnson et al, 1990; Masuda et al, 1992; Le Chevalier
et al, 1997). Moreover, CPT-11 or ETOP-containing combined
chemotherapy regimens showed favourable results, with response
rates of 20–88% and an MST of 4.7–8.7 months (Table 4)
(Evans et al, 1985; Masuda et al, 1990; Sculier et al, 1990; Gridelli
et al, 1991; Roth et al, 1992; Faylona et al, 1995; Kubota et al,
1997; Masuda et al, 1998; Groen et al, 1999; Nakanishi et al, 1999;
von Pawel et al, 1999; Domine et al, 2001; Kosmas et al,
2001). Therefore, these two drugs are considered to be key
drugs for the treatment of relapsed SCLC. In particular, the
combination of CPT-11 and ETOP (a combination of topoisome-
rase I and II inhibitors) produced a high response rate (71%)
and the best survival results (MST, 8.7 months) (Masuda et al,
1998). In addition, a weekly chemotherapy regimen containing
ETOP (CODE) was highly active in patients with relapsed
SCLC, with a favourable response rate (88%) and survival duration
(MST, 8.2 months) (Kubota et al, 1997). In the two studies
mentioned above, four patients (16%) with refractory relapsed
SCLC were included in the CPT-11 and ETOP study, and six
patients (35%) with refractory relapsed SCLC were included in the
CODE study. Three and five of these patients achieved PR,
respectively.
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Figure 3 Progression-free survival (n¼40).
Table 2 Haematological toxicities (JCOG toxicity criteria)
01234
% of Grs 3
and 4
Leucocytopenia 2 3 13 17 5 55
Neutropenia 3 4 4 12 17 73
Anemia 2 4 16 18 — 45
Thrombocytopenia 10 7 10 7 6 33
Elevated total bilirubin 33 — 6 1 0 3
Elevated GOT 32 7 0 1 0 3
Elevated GPT 30 7 2 1 0 3
Elevated creatinine 37 3 0 0 0 0
Hyponatremia 28 4 6 0 2 5
Hypokalemia 32 5 3 0 0 0
Grs¼grades; GOT¼glutamic oxaloacetic transaminase; GPT¼glutamic pyruvic
transaminase.
Table 3 Nonhaematological toxicities (JCOG toxicity criteria)
01234 % o f G r s 3 a n d 4
PS 1 30 4 5 0 13
Infection 28 4 7 1 0 3
Fever 29 7 4 0 0 0
Nausea/vomiting 11 15 11 3 — 8
Diarrhoea 15 16 6 2 1 8
Mucositis 36 4 0 0 0 0
Arrythmia 36 2 0 1 1 5
Eruption 37 1 1 1 0 3
Alopecia 16 17 7 — — —
Allergy 39 0 1 0 0 0
Grs¼grades; PS¼performance status.
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lThe response and survival data from Japanese clinical trials
for relapsed SCLC were generally better than those obtained
in western countries. We have no proof that this difference
depends on either drug metabolism or tumour sensitivity. It
is possibly related to the difference in patient follow-up interval
between Japan and western countries. Since intensive follow
up after completion of first-line treatment is common in
Japan, relapses can be detected in the early stage by CT or
MRI before becoming symptomatic. Therefore, relapsed patients
had a relatively good performance status, and showed good
responses to second-line chemotherapy as well as better survival
results.
The weekly regimen was designed to increase the overall relative
dose intensity of the chemotherapeutic drugs (Murray et al, 1991).
However, several phase III trials have made it clear that intensive
weekly chemotherapy does not improve the survival of patients
with SCLC (Furuse et al, 1998; Murray et al, 1999). On the other
hand, drug dosages and treatment schedules are easy to modify in
weekly chemotherapy regimens. Since patients with relapsed SCLC
may have lower bone marrow reserve, a high-dose regimen or
intensified dosage can lead to treatment-related death (Masuda
et al, 1990; Faylona et al, 1995). In the PEI regimen, the individual
dosage of each drug is within the commonly used range and the
dose given at one time is lower than that of a standard 3-week cycle
regimen. The PEI regimen therefore permits greater flexibility in
dosage adjustment and treatment delays based on laboratory data
or the physical condition of patients. Thus, this regimen is
considered to be suitable for the treatment of patients with relapse
SCLC. In addition, this weekly schedule may be of great advantage
for enabling the synergistic effects of ETOP (a topoisomerase II
inhibitor) and CPT-11 to be realised because the development of
resistance to topoisomerase II inhibitors has been reported to
increase tumour sensitivity to subsequent treatment with topoi-
somerase I inhibitors (Vasey and Kaye, 1997).
Three cytotoxic drugs were used in this PEI regimen. However,
three-drug combination chemotherapy was reportedly associated
with more severe toxicity and showed no survival benefit as
compared with the two-dug combination (Mavroudis et al, 2001;
Niell et al, 2002). The main reason for mild toxicities was that the
PEI regimen consists of a weekly schedule. With a weekly
chemotherapy regimen, drug dosages and treatment schedules
can easily be adjusted according to haematological data and the
patient’s physical condition. These careful modifications resulted
in a mild toxicity profile with the PEI regimen. Moreover, the PEI
regimen did not consist of concomitant administration of three
drugs but rather weekly alternative administration of a two-drug
combination chemotherapy, that is, PE and IP. As a result, the
toxicity profile was similar with that of two-drug combination
chemotherapy.
Although all the patients in this study were sensitive relapsed
cases, the overall response rate of 78% is one of the best results
reported for relapsed SCLC. Moreover, although only selected
patients with a good performance status were included in this
study, it is notable that the median survival time was 11.8 months
and the 1-year survival rate was 49%. In JCOG- 9511, the MST was
12.8 months in the IP arm and 9.4 months in the PE arm for
chemotherapy naive ED SCLC patients (Noda et al, 2002). Our
survival data for PEI is almost equivalent to that of first-line
treatment. Salvage chemotherapy may be possible to prolong the
survival of sensitive relapsed SCLC patients who are in good
physical condition.
Since second-line chemotherapy for relapsed SCLC patients is a
palliative treatment, a reasonable toxicity profile is essential. The
main toxicities of the PEI regimen were haematological. Although
G-CSF was routinely administered, Grades 3–4 leucopenia and
neutropenia were observed in 55 and 73% of patients, respectively.
Grades 3–4 thrombocytopenia was observed in 33% of patients.
However, the frequencies of these haematological toxicities were
approximately equal to that of first-line PE treatment (Noda et al,
2002). Nonhaematological toxicities were mild and transient in all
patients. Grades 3–4 diarrhoea was noted in only three patients
(8%). Irinotecan dose modifications as a result of haematological
toxicities were only performed in six patients (15%). All toxicities
were easily manageable, and no treatment-related deaths occurred.
In conclusion, PEI is a highly active and well-tolerated treatment
for sensitive relapsed SCLC. Another phase II trial restricted to
refractory relapsed SCLC patients is presently being performed by
our clinical group. Further phase III studies comparing PEI
regimen with rechallenges of the same drugs used in the first-line
chemotherapy regimen should clarify the role of second-line
chemotherapy for sensitive relapsed SCLC and are now being
planned.
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lomustine; MTX¼methotrexate; IFO¼ifosfamide; CODE¼cisplatin/vincristine/
doxorubicin/etoposide; CPT-11¼irinotecan; ETOP¼etoposide; CDDP¼cisplatin;
GEM¼gemcitabine; PTX¼paclitaxel; CBDCA¼carboplatin; NM¼not mentioned.
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